Moleculera Biosciences develops precision‑medicine tools that identify immune‑mediated root causes of chronic neuropsychiatric, cardiovascular disorders and Alzheimer’s disease. Their platform combines blood‑based autoantibody testing panels, a curated biorepository of phenotypically annotated specimens, and a biomarker discovery program, enabling clinicians to diagnose treatable autoimmune dysfunctions—such as with their FDA‑cleared Autoimmune Brain Panel™ of five high‑complexity blood tests. This approach supports personalized treatment plans aimed at resolving or markedly reducing symptoms.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with chronic neuropsychiatric, cardiovascular disorders and Alzheimer’s disease often receive symptom‑focused treatment without understanding whether an underlying immune‑mediated dysfunction is driving their condition. This lack of precise diagnosis leads to ineffective therapies, prolonged suffering, and higher healthcare costs.
Solution
Moleculera Biosciences offers a precision‑medicine platform that identifies immune‑mediated root causes of these chronic diseases. The core of the platform is a suite of blood‑based autoantibody testing panels, including the FDA‑cleared Autoimmune Brain Panel™ and emerging cardiovascular and Alzheimer’s panels. By detecting disease‑specific autoantibodies, clinicians can distinguish autoimmune contributions from primary neurological or psychiatric etiologies. Results are integrated with a curated, longitudinal biobank of phenotypically annotated specimens, enabling clinicians to match patients with targeted therapeutic strategies and monitor outcomes over time. The platform also supports biomarker discovery for new companion diagnostics and therapeutic targets, fostering ongoing innovation in immune‑mediated disease management.
Target Audience
Primary customers are neurologists, psychiatrists, cardiologists, and geriatric specialists seeking objective, immune‑based diagnostics to guide personalized therapy for patients with treatment‑resistant neuropsychiatric, cardiovascular, or Alzheimer’s disease symptoms.
Features
- Five high‑complexity blood tests in the Autoimmune Brain Panel™ that detect autoantibodies linked to anxiety, OCD, tics, depression, ADHD, chronic fatigue, autism, Lyme disease, seizures, PANS/PANDAS, and other neuropsychiatric symptoms
- Additional Autoimmune Cardiovascular and Alzheimer’s Early‑Intervention Inflammatory Biomarker panels targeting immune dysfunction in heart disease and neurodegeneration
- Curated, longitudinal biobank of clinically annotated specimens linked to treatment outcomes for research and personalized care
- Integrated biomarker discovery program that identifies novel diagnostic targets and therapeutic candidates using real‑world data
- Secure, CLIA‑certified laboratory testing with results delivered to clinicians for immediate incorporation into treatment plans